Revised Procedures for Non-Disclosure Agreements (NDA)


NEW -  Important Information for Investigators with International Collaborations

Revised Procedures for Non-Disclosure Agreements (NDA)

In an effort to reduce the time from request to execution of all clinical trial-related non-disclosure agreements (NDA) the Office of Technology Licensing and Industry Relations (OTLIR) has revised the procedure by which all clinical trial-related NDAs are being processed.  OTLIR thanks you for your compliance with the following procedure.  

1- Effective immediately, all requests for clinical trial-related NDAs must be sent to along with an editable copy of the NDA and the name of the clinician that will be receiving confidential information under the NDA.  Please note, that if is not copied on your request, your agreement may not be processed in a timely fashion.  

2- Effective Monday, March 18, 2019, clinicians will no longer be required to sign clinical trial-related NDAs as "read and understood" or "read and acknowledged."  However, the appropriate clinician will be copied on OTLIR correspondence reporting/providing a copy of the fully-executed clinical trial NDA.  Note this pertains only to clinical trial NDAs, not to other NDAs, which still require a "read and understood' acknowledgement.

Go to top